Linked Life Data

18657584

Source:http://linkedlifedata.com/resource/pubmed/id/18657584

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
37
pubmed:dateCreated
2008-8-25
pubmed:abstractText
The effectiveness of plasmid DNA (pDNA) vaccines can be improved by the co-delivery of plasmid-encoded molecular adjuvants. We evaluated pDNAs encoding GM-CSF, Flt-3L, IL-12 alone, or in combination, for their relative ability to serve as adjuvants to augment humoral and cell-mediated immune responses elicited by prototype pDNA vaccines. In Balb/c mice we found that co-administration of plasmid-based murine GM-CSF (pmGM-CSF), murine Flt-3L (pmFlt-3L) or murine IL-12 (pmIL-12) could markedly enhance the cell-mediated immune response elicited by an HIV-1 env pDNA vaccine. Plasmid mGM-CSF also augmented the immune response elicited by DNA vaccines expressing HIV-1 Gag and Nef-Tat-Vif. In addition, the use of pmGM-CSF as a vaccine adjuvant appeared to markedly increase antigen-specific proliferative responses and improved the quality of the resulting T-cell response by increasing the percentage of polyfunctional memory CD8(+) T cells. Co-delivery of pmFlt-3L with pmGM-CSF did not result in a further increase in adjuvant activity. However, the co-administration of pmGM-CSF with pmIL-12 did significantly enhance env-specific proliferative responses and vaccine efficacy in the murine vaccinia virus challenge model relative to mice immunized with the env pDNA vaccine adjuvanted with either pmGM-CSF or pmIL-12 alone. These data support the testing of pmGM-CSF and pmIL-12, used alone or in combination, as plasmid DNA vaccine adjuvants in future macaque challenge studies.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0264-410X
pubmed:author
pubmed:issnType
Print
pubmed:day
2
pubmed:volume
26
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
4819-29
pubmed:meshHeading
pubmed-meshheading:18657584-AIDS Vaccines, pubmed-meshheading:18657584-Adjuvants, Immunologic, pubmed-meshheading:18657584-Animals, pubmed-meshheading:18657584-CD8-Positive T-Lymphocytes, pubmed-meshheading:18657584-Cell Proliferation, pubmed-meshheading:18657584-Female, pubmed-meshheading:18657584-Granulocyte-Macrophage Colony-Stimulating Factor, pubmed-meshheading:18657584-HIV-1, pubmed-meshheading:18657584-Interleukin-12, pubmed-meshheading:18657584-Membrane Proteins, pubmed-meshheading:18657584-Mice, pubmed-meshheading:18657584-Mice, Inbred BALB C, pubmed-meshheading:18657584-Plasmids, pubmed-meshheading:18657584-Vaccines, DNA, pubmed-meshheading:18657584-env Gene Products, Human Immunodeficiency Virus, pubmed-meshheading:18657584-gag Gene Products, Human Immunodeficiency Virus, pubmed-meshheading:18657584-tat Gene Products, Human Immunodeficiency Virus
pubmed:year
2008
pubmed:articleTitle
Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines.
pubmed:affiliation
Wyeth Vaccines Research, Pearl River, NY 10992, United States.
pubmed:publicationType
Journal Article